The 30th birthday of chronic ulcerative stomatitis: A systematic review.

Astrid Herzum, Martina Burlando, Emanuele Cozzani, Aurora Parodi
{"title":"The 30th birthday of chronic ulcerative stomatitis: A systematic review.","authors":"Astrid Herzum,&nbsp;Martina Burlando,&nbsp;Emanuele Cozzani,&nbsp;Aurora Parodi","doi":"10.1177/20587384211052437","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Chronic ulcerative stomatitis (CUS) is a chronic, ulcerative condition of the oral cavity, clinically and histologically similar to oral lichen planus (OLP), first described as a new disease entity in 1990 by Parodi et al. In this review, 30 years after our first description of CUS, we aimed to systematically review the literature of CUS cases reported ever since.</p><p><strong>Methods: </strong>We present a systematic review of CUS literature cases, performed in compliance with the PRISMA statement.</p><p><strong>Results: </strong>Of 125 retrieved articles, 20 satisfied inclusion criteria. These described 76 CUS cases, all presenting orally evident disease: erosions (55%), white lesions (49%), erythema (49%), ulcerations (34%) were the most frequent signs; 54% experienced discomfort/pain. Topographically, buccal mucosa (68%) and gingiva (54%) were the most affected locations, followed by tongue (42%), hard palate (27%), labial mucosa (22%), and widespread involvement (15%). Great diagnostic delay (6.3 years) was evidenced highlighting CUS is an entity too often misdiagnosed. Histopathology found lichenoid features (46%) and non-specific inflammation (54%). Extra-oral involvement was reported in 21%, especially as LP (69%). Of DIF, 97% were positive; 3% negative, compensated by positive IIF, permitting diagnosis. Of patients on steroids, only 12% reported therapeutic success; most steroid-non-responsive patients passed to antimalarials, with 91.66% success when used alone, 100% success in combination therapy.</p><p><strong>Conclusion: </strong>Dermatologists should suspect CUS in chronic steroid-unresponsive erosive/ulcerative stomatitis. In these cases, to diagnose CUS, the presence of stratified epithelium-specific antinuclear antibodies (SES-ANA) should be investigated through immunofluorescence. Once diagnosed, CUS can be treated with antimalarials, which are an effective treatment contrarily to corticosteroids.</p>","PeriodicalId":14046,"journal":{"name":"International Journal of Immunopathology and Pharmacology","volume":"35 ","pages":"20587384211052437"},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/34/10.1177_20587384211052437.PMC8532222.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Immunopathology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20587384211052437","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives: Chronic ulcerative stomatitis (CUS) is a chronic, ulcerative condition of the oral cavity, clinically and histologically similar to oral lichen planus (OLP), first described as a new disease entity in 1990 by Parodi et al. In this review, 30 years after our first description of CUS, we aimed to systematically review the literature of CUS cases reported ever since.

Methods: We present a systematic review of CUS literature cases, performed in compliance with the PRISMA statement.

Results: Of 125 retrieved articles, 20 satisfied inclusion criteria. These described 76 CUS cases, all presenting orally evident disease: erosions (55%), white lesions (49%), erythema (49%), ulcerations (34%) were the most frequent signs; 54% experienced discomfort/pain. Topographically, buccal mucosa (68%) and gingiva (54%) were the most affected locations, followed by tongue (42%), hard palate (27%), labial mucosa (22%), and widespread involvement (15%). Great diagnostic delay (6.3 years) was evidenced highlighting CUS is an entity too often misdiagnosed. Histopathology found lichenoid features (46%) and non-specific inflammation (54%). Extra-oral involvement was reported in 21%, especially as LP (69%). Of DIF, 97% were positive; 3% negative, compensated by positive IIF, permitting diagnosis. Of patients on steroids, only 12% reported therapeutic success; most steroid-non-responsive patients passed to antimalarials, with 91.66% success when used alone, 100% success in combination therapy.

Conclusion: Dermatologists should suspect CUS in chronic steroid-unresponsive erosive/ulcerative stomatitis. In these cases, to diagnose CUS, the presence of stratified epithelium-specific antinuclear antibodies (SES-ANA) should be investigated through immunofluorescence. Once diagnosed, CUS can be treated with antimalarials, which are an effective treatment contrarily to corticosteroids.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性溃疡性口炎30岁生日:一项系统综述。
目的:慢性溃疡性口炎(CUS)是一种口腔慢性溃疡性疾病,临床和组织学上与口腔扁平苔藓(OLP)相似,Parodi等人于1990年首次将其描述为一种新的疾病实体。在这篇综述中,在我们首次描述CUS 30年后,我们旨在系统地回顾自那时以来报道的CUS病例的文献。方法:我们根据PRISMA声明对CUS文献病例进行系统回顾。结果:125篇检索文献中,20篇符合纳入标准。本文描述了76例CUS病例,均表现为口腔明显疾病:最常见的症状是糜烂(55%)、白色病变(49%)、红斑(49%)、溃疡(34%);54%的人感到不适/疼痛。从地形上看,口腔黏膜(68%)和牙龈(54%)是最受影响的部位,其次是舌头(42%)、硬腭(27%)、唇黏膜(22%)和广泛受累(15%)。诊断延迟大(6.3年),突出了CUS是一个经常误诊的实体。组织病理学发现地衣样特征(46%)和非特异性炎症(54%)。口腔外受累21%,尤其是LP(69%)。97%的DIF阳性;3%阴性,IIF阳性补偿,允许诊断。服用类固醇的患者中,只有12%报告治疗成功;大多数类固醇无反应的患者转而使用抗疟药物,单独使用时成功率为91.66%,联合治疗时成功率为100%。结论:皮肤科医生应怀疑慢性类固醇无反应性糜烂性/溃疡性口炎为CUS。在这些病例中,为了诊断CUS,应通过免疫荧光检测分层上皮特异性抗核抗体(SES-ANA)的存在。一旦确诊,可使用抗疟药物治疗,这是一种与皮质类固醇相反的有效治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.00
自引率
0.00%
发文量
88
审稿时长
15 weeks
期刊介绍: International Journal of Immunopathology and Pharmacology is an Open Access peer-reviewed journal publishing original papers describing research in the fields of immunology, pathology and pharmacology. The intention is that the journal should reflect both the experimental and clinical aspects of immunology as well as advances in the understanding of the pathology and pharmacology of the immune system.
期刊最新文献
Resveratrol promotes the differentiation of human umbilical cord mesenchymal stem cells into esophageal fibroblasts via AKT signaling pathway Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway Macrophage-derived exosomal miRNA-141 triggers endothelial cell pyroptosis by targeting NLRP3 to accelerate sepsis progression
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1